Why VIVUS Lost in November

VIVUS' (Nasdaq: VVUS  ) stock was down 25% for November, though still up 15% for the year. Its drug Qsymia is the first obesity drug to be approved and reach the market in more than a decade, but its sales are lagging. Because only 20% of patients are able to get the drug covered by insurance, there is currently a 30% abandonment rate of patients who decide they can't afford to keep taking it. The stock did rally a bit at the end of the month when Aetna announced that it would begin covering Qsymia and Arena's (Nasdaq: ARNA  ) Belviq in the same space, so investors are optimistic that as insurance coverage widens, sales will improve.

The ravages of America's obesity epidemic are a challenge of epic proportions. However, a group of drug companies is looking to change everything. Newly approved drugs, including Qsymia, could help to reverse this deadly course while reaping massive profits for investors in the process. The profit opportunity is immense but plenty of risks still exist, so make sure you understand the full story behind VIVUS in the Fool's brand new premium research service. It's such an important story that we have our top health care writer on the job, so make sure to secure a copy today by clicking here now.


Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2139143, ~/Articles/ArticleHandler.aspx, 4/19/2014 6:12:44 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement